Sign up to save your podcasts
Or
Share Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By The Wall Street Journal & Spotify Studios
4.2
56015,601 ratings
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like The Journal.
View all
Planet Money
30,732 Listeners
WSJ Opinion: Potomac Watch
2,834 Listeners
WSJ Your Money Briefing
1,707 Listeners
WSJ What’s News
4,329 Listeners
WSJ Tech News Briefing
1,645 Listeners
The Daily
111,970 Listeners
WSJ Minute Briefing
681 Listeners
Up First from NPR
56,511 Listeners
Bold Names
1,446 Listeners
Today, Explained
10,217 Listeners
Post Reports
5,461 Listeners
Barron's Streetwise
1,567 Listeners
Hard Fork
5,512 Listeners
The Ezra Klein Show
15,833 Listeners
Bad Bets
1,323 Listeners
WSJ Opinion: Free Expression
598 Listeners
As We Work
151 Listeners
WSJ's Take On the Week
144 Listeners